Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for HIV Pre-Exposure Prophylaxis (PrEP): A Pooled Observational Study

12/07/2018
23/04/2024
EU PAS number:
EUPAS24332
Study
Finalised
Documents
Study protocol
Initial protocol
English (447.12 KB - PDF) View document
Study results
Study results
English (2.27 MB - PDF) View document
Study report
Other information